![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Finds AstraZeneca’s Farxiga Falls Short for Type 1 Diabetes
FDA Finds AstraZeneca’s Farxiga Falls Short for Type 1 Diabetes
![AstraZeneca](https://www.fdanews.com/ext/resources/test/Device_Images2/AstraZeneca.gif?t=1576126438&width=430)
July 29, 2019
The FDA shot down AstraZeneca’s Farxiga (dapagliflozin) as an adjunct treatment to insulin for type 1 diabetes patients in a complete response letter to the company on Monday.
The once-daily oral medication is a selective SGLT2 inhibitor, one of a group of prescription drugs cleared by the agency for use in conjunction with dieting and exercise to lower blood sugar in adults with type 2 diabetes.
“The safety and efficacy of SGLT2 inhibitors have not been established in patients with type 1 diabetes, and FDA has not approved them for use in these patients,” the agency said.
Upcoming Events
-
21Oct